Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
Lucas Hendrik OvereemAndreas PeikertMaxi Dana HofackerKatharina KammRuth RuscheweyhAstrid GendollaBianca RaffaelliUwe ReuterLars NeebPublished in: Cephalalgia : an international journal of headache (2021)
Our findings demonstrate that a relevant proportion of erenumab non-responders might benefit from a treatment switch to a CGRP-mAb. Switching seems to be a promising treatment option especially in migraine patients with non-daily headache.
Keyphrases